ALGN vs. MRNA: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and MRNA, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
With ALGN at 12.46 billion USD and MRNA at 9.98 billion USD, their market capitalizations sit in the same ballpark.
With betas of 1.68 for ALGN and 2.00 for MRNA, both show similar volatility profiles relative to the overall market.
| Symbol | ALGN | MRNA |
|---|---|---|
| Company Name | Align Technology, Inc. | Moderna, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Biotechnology |
| CEO | Mr. Joseph M. Hogan | Mr. Stephane Bancel |
| Price | 171.91 USD | 25.8 USD |
| Market Cap | 12.46 billion USD | 9.98 billion USD |
| Beta | 1.68 | 2.00 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | December 7, 2018 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALGN and MRNA over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALGN and MRNA based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- MRNA shows a negative P/E of -2.97, highlighting a year of losses, whereas ALGN at 30.88 trades on solid profitability.
- MRNA reports a negative Price-to-Free Cash Flow ratio of -2.48, showing a cash flow shortfall that could threaten its operational sustainability, while ALGN at 19.76 maintains positive cash flow.
| Symbol | ALGN | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 30.88 | -2.97 |
| Forward PEG Ratio (TTM) | 2.92 | 0.11 |
| Price-to-Sales Ratio (P/S, TTM) | 3.13 | 3.16 |
| Price-to-Book Ratio (P/B, TTM) | 3.33 | 0.99 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 19.76 | -2.48 |
| EV-to-EBITDA (TTM) | 14.56 | -2.85 |
| EV-to-Sales (TTM) | 2.94 | 2.88 |
| EV-to-Free Cash Flow (TTM) | 18.56 | -2.26 |
Dividend Comparison
Neither ALGN nor MRNA currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALGN and MRNA, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALGN shows “--” (minimal interest expense), but MRNA is in the red with interest coverage -207.17, signaling a net operating loss.
| Symbol | ALGN | MRNA |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 4.22 |
| Quick Ratio (TTM) | 1.08 | 4.14 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 0.07 |
| Debt-to-Assets Ratio (TTM) | 0.02 | 0.06 |
| Interest Coverage Ratio (TTM) | -- | -207.17 |